The field of fine chemistry is constantly evolving, with new compounds and intermediates driving innovation across industries, especially in pharmaceuticals. Ethyl (1-Benzylpiperidin-4-ylidene)acetate, known by its CAS number 40110-55-2, is one such compound that holds significant promise. Its synthesis, often involving the reaction of 1-Benzyl-4-piperidone, is a critical step in making it available for various applications. Understanding these chemical synthesis routes is fundamental for chemists working with this substance.

As a vital pharmaceutical intermediate, Ethyl (1-Benzylpiperidin-4-ylidene)acetate, with its molecular formula C16H21NO2 and molecular weight of 259.34, serves as a key building block for many drug molecules. Its typical form as a white or light yellow crystalline powder indicates a purity level essential for pharmaceutical applications. This characteristic ensures that downstream synthesis steps are not compromised by impurities, a crucial aspect when aiming to buy high-grade API intermediate chemical products.

Ningbo Inno Pharmchem Co., Ltd. is a provider of these essential chemical research chemicals. We recognize that the ability to reliably source such compounds from reputable suppliers is paramount for the success of research and development projects. Whether you are exploring new organic synthesis methods or need established pharmaceutical intermediate materials, our product offerings aim to meet your exacting demands. The efficient production of these intermediates directly impacts the ability to develop life-saving medications.

The journey from a raw chemical to a finished pharmaceutical product is complex, and intermediates like Ethyl (1-Benzylpiperidin-4-ylidene)acetate form crucial links in that chain. By focusing on accessible synthesis pathways and ensuring product availability, Ningbo Inno Pharmchem Co., Ltd. supports the broader scientific community in advancing their research and development goals. Exploring the potential of these compounds is key to unlocking future therapeutic innovations.